Represents the amortization of capitalized fees paid to a related party.

No definition available.

Name:	inva_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of additional preclinical MABA compounds added to the MABA program.

+ References

No definition available.

+ Details

Name:	inva_CollaborationArrangementObligationToDiscoverPreclinicalCompounds
Namespace Prefix:	inva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate for combination products.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential future contingent payments that the entity is eligible to receive.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementContingentPaymentThatEntityCouldEarn
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of registrational and launch-related milestone fee paid under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRegistrationalAndLaunchRelatedMilestoneFeesPaid
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of contingent payments and royalties receivable for sales made by the entity.

+ References

No definition available.

+ Details

Name:	inva_ContingentPaymentsAndRoyaltiesReceivableAsPercent
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of milestone payment which company is entitled to receive.

+ References

No definition available.

+ Details

Name:	inva_EligiblePercentageOfMilestonePayment
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property, excluding revenue from collaborative arrangements. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents.

+ References

No definition available.

+ Details

Name:	inva_RoyaltyRevenueFromRelatedPartyNet
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Related Parties
-URI http://asc.fasb.org/extlink&oid=16382449

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LABACollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COLLABORATIVE ARRANGEMENTS (Details) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
COLLABORATIVE ARRANGEMENTS (Details) $ in Thousands	Oct. 31, 2011 item	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party										$ (13,823)	$ (13,823)	$ (11,066)
Royalty revenue										132,684	53,064	7,351
Strategic alliance - MABA program license										885	885	1,082
Total net revenue		$ 43,612	$ 33,309	$ 32,472	$ 24,176	$ 22,836	$ 13,562	$ 10,655	$ 6,896	133,569	53,949	8,433
GSK
Information related to collaborative arrangements
Total net revenue										133,569	53,949	8,433
Long-acting beta agonist (LABA) collaboration \| GSK
Information related to collaborative arrangements
Royalties from a related party		46,800								146,507	66,887	18,417
Less: amortization of capitalized fees paid to a related party										(13,823)	(13,823)	(11,066)
Royalty revenue										$ 132,684	53,064	7,351
Milestone fees paid												220,000
Royalty rate for first level of annual global net sales (as a percent)										15.00%
Annual global sales level used to determine royalty rate										$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)										5.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)										6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)										10.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| RELVAR/BREO
Information related to collaborative arrangements
Royalties from a related party										$ 128,638	59,188	16,635
Long-acting beta agonist (LABA) collaboration \| GSK \| ANORO
Information related to collaborative arrangements
Royalties from a related party										17,869	7,699	1,782
Strategic alliance - MABA program license \| GSK
Information related to collaborative arrangements
Strategic alliance - MABA program license										$ 885	$ 885	$ 1,082
Number of preclinical MABA compounds discovered \| item	6
Contingent payments and royalties receivable (as a percent)										15.00%
Percentage of milestone payment										15.00%
Strategic alliance - MABA program license \| GSK \| Maximum
Information related to collaborative arrangements
Potential future contingent payments receivable		$ 363,000								$ 363,000
Strategic alliance - MABA program license \| Theravance Biopharma Spinoff
Information related to collaborative arrangements
Contingent payments and royalties receivable (as a percent)										85.00%